Amgen has solidified its position in the biotech sector with the acquisition of Horizon Therapeutics for $28.3 billion, coinciding with a $300 million investment to expand its U.S. biologics manufacturing capabilities. Despite challenges posed by increasing biosimilar competition, Amgen has raised its 2026 revenue guidance to between $37.1 billion and $38.5 billion, reflecting confidence in its robust product pipeline. The company's participation in the FDA's real-time clinical trials initiative further reinforces its commitment to advancing innovative therapies.
“Horizon Therapeutics · was acquired by · Amgen · $28.3 billion”
“Amgen · has a role in · FDA's real-time clinical trials initiative · true”
“Amgen · initiated · Phase 1b STREAM-SCLC study · true”
“Amgen · is at the forefront of · continuous trial frameworks · true”
“Amgen · will present · at the Bank of America Merrill Lynch Global Healthcare Conference · 10:00 a.m. PT on Wednesday, May 13, 2026”
“Peter Griffith · is the · executive vice president and chief financial officer at Amgen”
“Jay Bradner · is the · executive vice president of Research and Development at Amgen”
“Amgen · has been selected by · US Food and Drug Administration · to participate in its real time clinical trials initiative”
“Amgen · will apply · the framework · to its Phase 1b STREAM SCLC trial in small cell lung carcinoma”
“Amgen · focuses on · biotechnology driven therapies · including oncology”
“Amgen · participation in · the FDA's real time clinical trials initiative · reflects how the company is approaching complex oncology programs”
“Amgen · began facing · biosimilar competition · for denosumab”
